Senhwa Biosciences, Inc. (TPEX:6492)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
50.00
-0.60 (-1.19%)
Mar 3, 2026, 11:09 AM CST
8.93%
Market Cap 4.51B
Revenue (ttm) 1.08M
Net Income (ttm) -263.96M
Shares Out 89.19M
EPS (ttm) -2.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 235,775
Average Volume 1,374,169
Open 51.60
Previous Close 50.60
Day's Range 49.50 - 51.60
52-Week Range 28.45 - 66.50
Beta 1.35
RSI 44.89
Earnings Date Mar 16, 2026

About Senhwa Biosciences

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidna... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6492
Full Company Profile

Financial Performance

In 2024, Senhwa Biosciences's revenue was 1.00 million, a change of 0.00% compared to the previous year's 1.00 million. Losses were -293.75 million, -0.86% less than in 2023.

Financial Statements

News

Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Basal Cell N...

6 months ago - Benzinga